Search

Ionis Pharmaceuticals Inc

Avatud

SektorTervishoid

60.77 2.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

58.44

Max

60.86

Põhinäitajad

By Trading Economics

Sissetulek

-22M

-115M

Müük

22M

268M

Aktsiakasum

-0.7

Kasumimarginaal

-42.787

Töötajad

1,480

EBITDA

-37M

-105M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+48.73% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

28. okt 2026

Turustatistika

By TradingEconomics

Turukapital

495M

9.7B

Eelmine avamishind

58.65

Eelmine sulgemishind

60.77

Uudiste sentiment

By Acuity

100%

0%

329 / 340 Pingereas Healthcare

Ionis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. aug 2026, 20:06 UTC

Ionis Pharmaceuticals Inc shares are higher, supported by strong momentum above the 20-day moving average. No specific news was identified for today's move.

17. aug 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Monday's close amid broader market weakness and geopolitical tensions.

14. aug 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-market trading. No specific news was identified to explain the movement amid broader economic concerns.

13. aug 2026, 19:56 UTC

Ionis Pharmaceuticals Inc shares are lower today, reflecting broader market trends. First-time unemployment claims rose, but overall investor sentiment remains stable.

12. aug 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

11. aug 2026, 23:46 UTC

Ionis Pharmaceuticals shares are higher in after-market trading, reaching a high near the upper end of their one-month range. No specific news was identified.

10. aug 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours. Broader market sentiment is cautious following weaker-than-expected labor market data.

7. aug 2026, 20:03 UTC

News

Ionis Pharmaceuticals shares are higher today amid increased market volume. HC Wainwright revised Q3 2026 loss estimates, maintaining a "Buy" rating.

6. aug 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5. aug 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4. aug 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3. aug 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1. aug 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31. juuli 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30. juuli 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

29. juuli 2026, 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

28. juuli 2026, 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

27. juuli 2026, 20:07 UTC

News
Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

25. juuli 2026, 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

24. juuli 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

23. juuli 2026, 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

22. juuli 2026, 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

21. juuli 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

20. juuli 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Võrdlus sarnastega

Hinnamuutus

Ionis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

48.73% tõus

12 kuu keskmine prognoos

Keskmine 88.67 USD  48.73%

Kõrge 115 USD

Madal 60 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Ionis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

16

Osta

4

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat